NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and commercializationAppointment follows commencement of Phase 2 RESOLVE-1 trial of oral NLRP3 inflammasome inhibitor NT-0796 in patients with obesity Philadelphia, PA, June 17, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Elisabeth Björk, M.D., Ph.D. as Board Member. Elisabeth has more than 20 years of experience in late-stage cl

ZUG, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced a summary of data that were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025. "Pharvaris embraced the opportunity to engage in scientific exchange with the HAE thought leader community during EAACI as we presented data supporting the differentiated profile of deucrictibant

ZUG, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 27, 2025, at 16:00 CEST (10:00 a.m. EDT). All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are or will be made available in the "Investors" section of Pharv

Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treatedFirst-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data supports potential for deucrictibant portfolioClinically validated biomarker assay has potential to eventually expand treatment opportunities of deucrictibant into additional forms of bradykinin-mediated angioedemaEpidemiologic data and cognitive interviews further elucidate the unmet needs in bradykinin-mediated angioedema ZUG, Switzerland, June 02, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagon

ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14th C1-Inhibitor Deficiency and Angioedema Workshop, to be held from May 29-June 1, 2025, in Budapest; the 2025 Eastern Allergy Conference (EAC), to be held from May 29-June 1, 2025, in Palm Beach, Fl.; and the European Academy of Allergy and Clin

Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Attack dataset continues to accumulate in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesTQT study waivers received from FDA for both deucrictibant extended-release formulation and deucrictibant immediate-release formulationPharvaris Management to host R&D call on June 4 at 8:00 a.m. ET (14.00 CET) ZUG, Switzerland, May 13, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor anta

ZUG, Switzerland, May 12, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE), including HAE with normal C1 inhibitor and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that it will host a virtual R&D call, titled "Deucrictibant: Beyond HAE Type 1/2" on Wednesday, June 4, at 8:00 a.m. ET/14:00 CET. The virtual event will explore the pathophysiology and prevalence of bradykinin-mediated angioedema, the current treatment paradigm and unmet needs of thos

Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesEnrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Orphan medicinal product designation granted to deucrictibant in Europe for the treatment of bradykinin-mediated angioedemaData presented at recent congresses reinforces the value of deucrictibant by highlighting its ability to maintain a reduced attack rate in long-term prophylaxis, and potential to rapidly and completely treat HAE attacks, including in participants experiencing upper-ai

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the European Commission (EC) has granted orphan designation to its investigational drug, deucrictibant, for the treatment of bradykinin-mediated angioedema. The U.S. Food and Drug Administration (FDA) previously granted orphan drug designation to deucrictibant for the treatment of bradykinin-mediated angioedema in M

Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero daysAll participants in CHAPTER-1 OLE who had reached week 62 reported improved health-related quality of lifeOngoing RAPIDe-2 extension study includes efficacy data from seven upper airway, including laryngeal, attacks; median time to onset of symptom relief was 0.9 hours (N=7)In both extension studies, deucrictibant was generally well tolerated with no safety signals observed ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradyki